Table F-8. Key Question 2 studies with a fourth outcome

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Feldstein et al., 200613 | G1: Usual care (not abstracted)G2: EMR reminder (increase reach for clinicians)G3: EMR reminder and patient reminder (via letter with educational materials (multicomponent) | Behavioral intentions to use or apply the evidencePhysical activity (affirmative response to the query, “At least once a week, do you engage in any regular activity long enough to break a sweat?”) | Baseline and 6 months after the interventionPatient self-report | G1: 33; G2: 41; G3: 42 | Post intervention=PercentG1: Pre 21.2; Post 30.3G2: Pre 22; Post 19.5 G3: Pre 26.2; Post 28.6 | Difference: G1 vs. G2: -10.8;\*G1 vs. G3: 1.7; \*G2 vs. G3: -9.1\*95% CI: NRp=0.55 treatment and UC | Presurvey responseRegression analysis between treatment and usual care groups with the change of the postsurvey response from presurvey as the DV adjusting for presurvey response |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Kennedy et al., 200319 | G1: Control (not abstracted)G2: Information (increase reach)G3: Interview (increase motivation) | Health-related decisions or behavior (applicable for general public/patients) Treatment undergone. For short-term, the treatment undergone is any treatment undergone up to 12 months. For long-term followup, the data presented are cumulative and refer to any treatment undergone during the period of the study. | The 6 and 12 month data were merged together to form a “short-term” followup dataset. 24 months is labeled “long-term”Self-report | Short-termOverall=631G2: 205G3: 221Long-termOverall=729G2: 232G3: 253 | Short-termG2: 170 (82.9%)G3: 186 (84.2%)Long-termG2: 204 (87.9%)G3: 212 (83.8%) | G2 vs. G3: 1.3%\*, p=NRLong term G2 vs. G3: 4.1%\*, p=NR | Consultant sex; Consultant year of qualification; Age; Baseline menorrhagia severity; Baseline knowledge; Previous treatment – D&C; Previous treatment – OCP; Previous treatment – hormonal drugs; Previous treatment – non-hormonal drugs; Duration of problem; Any previous surgery; Baseline preferences; Recruitment period; Length of followupLogistic regression |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Marcus et al., 200925 | G1: Contact control treatment delayed group (not abstracted)G2: Telephone-based individualized feedback (increase motivation)G3: Print-based individualized feedback (increase reach) | Health-related decisions or behavior (applicable for general public/patients) Physical activity minutes per week via self-report on PAR (interviewer administered 7-day Physical Activity Recall) interview | Baseline, 6 months and 12 monthsSelf-report | Overall N=218 at 6 months; 205 at 12 monthsG1: 72 at 6 months, 69 at 12 monthsG2: 75 at 6 months, 70 at 12 months G3: 71 at 6 months, 66 at 12 months | G1: 6 months: 77.67 (SD=101.79); 12 months: 81.92 (SD=127.07)G2: 6 Months: 123.32 (SD=97.64) 12 Months: 100.59 (SD=119.68) G3: 6 Months: 129.49 (SD=156.46) 12 Months: 162.37 (SD=165.17) | Difference: 6 months: 6.17 12 months: 61.78 95% CI: NRP: 6 months: t = 0, p=0.8595 12 months: (t=2.72, p=0.0071) | YesAnalysis of covariance, adjusted for treatment effects for gender and seasonal differences. When overall test of between-groups differences was significant at the >05 level, the source of these differences was examined further using single-degree-of-freedom contrasts that compared the active treatment arms with each other as well as with the treatment delayed group. |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Murtaugh et al., 200527 | G1: Usual care (not abstracted)G2: Basic intervention email reminder (increase reach)G3: Augmented intervention of email reminder + package of supporting materials (multicomponent) | Behavior (applicable for clinicians) % performing comprehensive CHF assessment | Chart-review of subsequent RN visit, within 45 days of initial intakeChart | 354 | Overall N=354G1: 3.7%G2: 13.8%G3: 23.9% | Difference G2-G1: 10.1%, p=0.006 Difference G3-G1: 20.2%, P<0.001Difference G3-G2: 10.1%\*, CI and p=NR | Sociodemo-graphic variables of the RN (age, gender, race/ethnicity), Rn employment status, educational level and caseload; average baseline characteristics of patients cared for by each RN including health, functional status; geographic area where nurse provided carePredictive multivariate modeling |
| Partin et al., 200429 | G1: Usual care (not abstracted)G2: Pamphlet (increase reach)G3: Video (increase reach) | Health-related decisions or behavior (applicable for general public/patients) PSA testing | 2 weeks and 1 year posttarget appointmentVA outpatient records | N=893G2: 295G3: 308 | Adjusted PSA rate w/in 2 weeksG2: 0.28 G3:0.29Adjusted PSA w/in 1 yearG2: 0.67G3: 0.70  | PSA w/in 2 weeksG2 vs. G3: -0.01\*, p=NRPSA w/in 1 yearG2 vs. G3: 0.70\*, p=NR | NoneLogistic regression |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Rebbeck et al., 200631 | G1: Dissemination of guidelines by mail (increase reach)G2: Implementation group (multicomponent) | Behavior (applicable for clinicians) Physiotherapist clinical practice - measured as the percentage of participating physiotherapists prescribing guideline recommendations | Before, during, and after the studyself-report | BeforeG1: 13G2: 14AfterG1: 12G2: 14DuringG1: 12G2: 14 | %Reassure patientBeforeG1: 41%G2: 14%AfterG1: 18%G2: 57%DuringG1: 14%G2: 46%Advise to act as usualBeforeG1: 8G2: 7AfterG1: 18G2: 67DuringG1: 0G2: 31Prescribe functionBeforeG1: 8G2: 7AfterG1: 0G2: 25DuringG1: 0G2: 23 | Reassure patientDifference (between G1 and G2 after trial): 39%\*p=0.05Advise to act as usualDifference (between G1 and G2 after trial): 49%\*p=0.04Prescribe functionDifference (between G1 and G2 after trial): 25%\*p=0.22Prescribe exerciseDifference (btn G1 and G2 after trial): 0%\*p=1.00Prescribe medicationDifference (btn G1 and G2 after trial): 1%\*p=0.10 | NRChi-square test |

Table F-8. Key question 2 studies with a fourth outcome (continued)

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Author,Year** | **Groups**  | **Outcome #, Exact measure used**  | **Timing of measurement,****Data Source**  | **N analyzed for this outcome**  | **Results by group** | **Differences in Groups**  | **Covariates controlled for in analysis, Statistical methods used,**  |
| Rebbeck et al., 200631 (continued) |  |  |  |  | Prescribe exerciseBeforeG1: 92G2: 100AfterG1: 100G2: 100DuringG1: 100G2: 83Prescribe medicationBeforeG1: 17G2: 7AfterG1: 9G2: 8DuringG1: 0G2: 23 |  |  |
| Wolters et al., 200539 | G1: Control mailed guidelines (increase reach)G2: Intervention involving package for learning, supporting materials, decision tree, and information leaflets for patients (multicomponent) | Discussions about the evidenceLifestyle advice given  | Up to 1 years post baselineSelf-report | N=187G1: 92G2: 95 | Lifestyle adviceG1: 52, 56.5%G2: 58, 61.1% | Lifestyle adviceG1 vs. G2: 4.6%\*OR: 1.32 (0.48/3.63) | Age, group allocation, IPSS and BSLogistic regression analysis |

\* calculated by reviewer
**Abbreviations:** BS=Bother score; btn=between; CHF = congestive heart failure; CI = confidence interval; D&C = dilation and curettage; DV = dependent variable; EMR = electronic medical record; G = group; IPSS=International Prostate Symptom Score; N=number; NR = not reported; OCP = oral contraceptive pill; PAR = Stanford 7-Day Physical Activity Recall; PSA = prostate-specific antigen; RN=registered nurse; SD = standard deviation; vs. = versus; w/in=within.